Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + FLAMSA + Treosulfan for Allogeneic Blood Stem Cell Transplantation in MDS, CMML or sAML
NCT05807932Phase 2Recruiting
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jun 2023
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Heinrich Heine University Düsseldorf. Started Jun 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05807932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807932.